Laura S. Haneline MD
Phone: 317-274-8916
Office: RI 2618

Laura S. Haneline, MD

Professor: Department of Pediatrics

Clinical Section: Neonatal-Perinatal Medicine

Basic Science Joint Appointment: Microbiology and Immunology


  • Postdoctoral Fellowship: Herman B Wells Center for Pediatric Research
  • Fellowship: Neonatal-Perinatal Medicine
  • Residency: Indiana University School of Medicine
  • MD: Indiana University School of Medicine

Research Interest:

In my laboratory, we conduct basic and translational research studies. The main focus of basic science studies is based on the hypothesis that a fetus exposed to a diabetic intrauterine environment alters the function of stem and progenitor cells with subsequent perturbations in the development and function of hematopoietic and vascular systems. My laboratory previously demonstrated that human endothelial colony forming cells (ECFCs) or putative endothelial progenitor cells from infants born to mothers with pre-gestational diabetes have increased oxidative damage and impaired vessel forming ability. Ongoing studies are exploring molecular mechanisms involved and whether these alterations are reversible. In addition, studies are investigating the distinct functional consequences of intrauterine exposure to gestational diabetes on fetal endothelial and hematopoietic progenitor cells compared to a pre-gestational diabetes environment. Recent translational research studies from my laboratory demonstrated that angiogenic progenitor cell subsets are reduced in cord blood and maternal blood samples from pregnancies complicated by gestational diabetes. These findings support the concept that measuring angiogenic progenitor cell subsets during pregnancy could serve as a novel biomarker to identify those at highest risk for vascular dysfunction. Based on these studies, we are involved in an NIH-funded Obsteric-Fetal Pharmacologic Research network that conducts basic and translational pharmacologic studies of drug disposition and effect on progenitor cell subsets during healthy and high-risk pregnancies. Because of our interest in using angiogenic cells as biomarkers of vascular and hematopoietic diseases, we are aslo funded by NIH as a Center for Pediatric Pharmacology within a multi-site network grant to conduct translational studies exploring circulating progenitor cells as biomarkers of chemotherapy efficacy and toxicity in pediatric patients.

Ongoing projects:

  1. Investigating the molecular mechanisms responsible for the premature aging phenotypes detected in ECFCs from infants born to women with type 2 diabetes
  2. Identifying distinct molecular mechanisms responsible for the functional defects in ECFCs from GDM pregnancies compared to ECFCs with type 2 diabetes
  3. Evaluating whether circulating progenitor cell subsets can be used to evaluate risk for gestational disorders associated with endothelial dysfunction
  4. Determining whether circulating progenitor cell subsets can serve as a biomarker of drug efficacy in pregnancy
  5. Examining whether circulating progenitor cell subsets can be used as a biomarker of chemotherapy induced drug toxicity and/or efficacy in children